FAM72 Serves As a Biomarker of Poor Prognosis in Human Lung Adenocarcinoma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Mar 9

PMID 33686947

Citations 17

Authors

Yilin Yu

Zhiping Wang

Qunhao Zheng

Jiancheng Li

Affiliations

Soon will be listed here.

Abstract

FAM72A-D promote the self-renewal of neural progenitor cells. There is accumulating evidence that FAM72 promotes tumorigenicity. However, its effects in lung adenocarcinoma (LUAD) have not been determined. Thus, we evaluated the prognostic value of in LUAD using bioinformatics approaches. In particular, we evaluated the relationship between FAM72 and LUAD using a wide range of databases and analysis tools, including TCGA, GEO, GEPIA, Metascape, cBioPortal, and MethSurv. Compared with its expression in normal lung tissues, FAM72 expression was significantly increased in LUAD tissues. A univariate Cox analysis showed that high FAM72 expression levels were correlated with a poor OS in LUAD. Additionally, FAM72 expression was independently associated with OS through a multivariate Cox analysis. GO and GSEA revealed enrichment in mitotic nuclear division and cell cycle. Moreover, high FAM72 expression was associated with poor survival. An analysis of immune infiltration showed that FAM72 is correlated with immune cell infiltration. Finally, we found that the methylation level was associated with prognosis in patients with LUAD. In summary, these results indicate that FAM72 is a potential molecular marker for poor prognosis in LUAD and provide additional insight for the development of therapies and prognostic markers.

Citing Articles

Identification of LIMK1 as a biomarker in clear cell renal cell carcinoma: from data mining to validation.

Li Y, Fan C, Jiang F, Zhang J, Li Y, Jiang Y J Cancer Res Clin Oncol. 2025; 151(3):104.

PMID: 40056237 PMC: 11890329. DOI: 10.1007/s00432-025-06146-5.

B-cell signatures characterize the immune landscape and predict LUAD prognosis via the integration of scRNA-seq and bulk RNA-seq.

Xu K, Han D, Fan Z, Li Y, Liu S, Liao Y Sci Rep. 2025; 15(1):5453.

PMID: 39953119 PMC: 11828960. DOI: 10.1038/s41598-025-89213-8.

A five-gene prognosis model based on lysine β-hydroxybutyrylation site genes to predict the survival and therapy response in pancreatic adenocarcinoma.

Hu F, Bai Z, Yan K, Zhang Z, Zhou J Heliyon. 2025; 10(14):e34284.

PMID: 39816360 PMC: 11734053. DOI: 10.1016/j.heliyon.2024.e34284.

Prognostic value and molecular mechanisms of OAS1 in lung adenocarcinoma.

Wang L, Gao L, Ding F, Gao K, Liu Q, Yin X BMC Pulm Med. 2024; 24(1):473.

PMID: 39334033 PMC: 11437775. DOI: 10.1186/s12890-024-03206-3.

The value analysis of high-resolution thin-layer CT in the identification of early lung adenocarcinoma: An observation study.

Zhao Z, Yang H, Wang W Medicine (Baltimore). 2024; 103(37):e39608.

PMID: 39287245 PMC: 11404865. DOI: 10.1097/MD.0000000000039608.

References

Nehar S, Mishra M, Heese K . Identification and characterisation of the novel amyloid-beta peptide-induced protein p17. FEBS Lett. 2009; 583(19):3247-53. DOI: 10.1016/j.febslet.2009.09.018. View

Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J . MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2017; 10(3):277-288. DOI: 10.2217/epi-2017-0118. View

Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y . Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC. Mol Cancer Res. 2017; 15(10):1354-1365. DOI: 10.1158/1541-7786.MCR-17-0191. View

Rahane C, Kutzner A, Heese K . Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature. Cancer Genet. 2018; 230:1-12. DOI: 10.1016/j.cancergen.2018.10.005. View

Yoon S, Shaikh T, Hallman M . Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017; 8(1):1-20. PMC: 5309711. DOI: 10.5306/wjco.v8.i1.1. View

Zhao S, Ye Z, Stanton R . Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. RNA. 2020; 26(8):903-909. PMC: 7373998. DOI: 10.1261/rna.074922.120. View

Patel S, Kurzrock R . PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14(4):847-56. DOI: 10.1158/1535-7163.MCT-14-0983. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Prince V, Pickett F . Splitting pairs: the diverging fates of duplicated genes. Nat Rev Genet. 2002; 3(11):827-37. DOI: 10.1038/nrg928. View

10.

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

11.

Rajan P, Stockley J, Sudbery I, Fleming J, Hedley A, Kalna G . Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer. 2014; 14:977. PMC: 4301544. DOI: 10.1186/1471-2407-14-977. View

12.

Borst J, Ahrends T, Babala N, Melief C, Kastenmuller W . CD4 T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018; 18(10):635-647. DOI: 10.1038/s41577-018-0044-0. View

13.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

14.

Chen D, Wang R, Yu C, Cao F, Zhang X, Yan F . FOX-A1 contributes to acquisition of chemoresistance in human lung adenocarcinoma via transactivation of SOX5. EBioMedicine. 2019; 44:150-161. PMC: 6607090. DOI: 10.1016/j.ebiom.2019.05.046. View

15.

Kutzner A, Pramanik S, Kim P, Heese K . All-or-(N)One - an epistemological characterization of the human tumorigenic neuronal paralogous FAM72 gene loci. Genomics. 2015; 106(5):278-85. DOI: 10.1016/j.ygeno.2015.07.003. View

16.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

17.

Chatonnet F, Pignarre A, Serandour A, Caron G, Avner S, Robert N . The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation. Haematologica. 2019; 105(3):774-783. PMC: 7049362. DOI: 10.3324/haematol.2019.222133. View

18.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

19.

Lin S, Wang J, Saintigny P, Wu C, Giri U, Zhang J . Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014; 15:1079. PMC: 4298954. DOI: 10.1186/1471-2164-15-1079. View

20.

Rahane C, Kutzner A, Heese K . A cancer tissue-specific FAM72 expression profile defines a novel glioblastoma multiform (GBM) gene-mutation signature. J Neurooncol. 2018; 141(1):57-70. DOI: 10.1007/s11060-018-03029-3. View